Crisax

Quick links to important sections

Crisax

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Crisax

What is Crisax? Defining the Drug's Identity

Property Description
Active Ingredients Bromocamphor, Phenobarbital, Potassium Bromide
Form Oral Medication (e.g., Tablet/Capsule)
Pharmacological Class Central Nervous System (CNS) Depressant
Common Use Sedative, Anxiolytic (Nervous Tension)
Origin Synthetic/Derived

Crisax is a prescription-only medicine and an oral medication classified as a Central Nervous System (CNS) Depressant, formulated to manage states of nervous excitability. This polypharmaceutical product is a fixed-dose combination (FDC), meaning its therapeutic effect relies on the combined action of three distinct active ingredients in a single preparation. The combination of ingredients for central nervous system modulation is clinically recognized for its sedative efficacy and has been featured in international pharmacopeias due to its historical use.

Composition: The Active Ingredients in Crisax

The preparation contains Phenobarbital, Potassium Bromide, and Bromocamphor. The composition is primarily synthetic/derived; Phenobarbital is a derivative belonging to the barbiturate class. The inclusion of a barbiturate establishes the drug's potent sedative profile. Historically, the Potassium Bromide component has been recognized for its generalized inhibitory action on the CNS, often contributing to a calming effect. Bromocamphor, a monobrominated camphor derivative, supports the overall tranquilizing action of the combination.

What is the General Purpose of Crisax?

The general purpose of Crisax is to promote a generalized calming effect by achieving the reduction of CNS excitability. The combined action of its three components works to stabilize the nervous system, which is utilized to help manage states of heightened tension, excessive irritability, and mild anxiety states. For example, it might be used to provide a sedative effect to an adult experiencing emotional lability or pervasive nervousness. Therefore, its role is defined within the scope of managing various nervous disorders, acting primarily as a combination sedative and anxiolytic preparation.

Regulatory References

  1. DailyMed Label for Kali Bromatum (Potassium Bromide)

What side effects are possible with Crisax?

Possible Side Effects and Safety Information

The safety profile of Crisax (Phenobarbital, Potassium Bromide, Bromocamphor) is formally documented based on the established regulatory classifications of its active components, which act as Central Nervous System (CNS) depressants.


Official Adverse Reaction Classifications

The adverse reactions are categorized in official labels based on frequency and affected body systems. These effects reflect the drug's primary action in the CNS:

  • Common Adverse Reactions: These are effects frequently observed in regulatory studies, primarily related to CNS depression. They include drowsiness (somnolence), sedation, dizziness, headache, and impaired coordination (ataxia). Mild gastrointestinal disturbances are also commonly noted.

  • Uncommon or Rare Adverse Reactions: Less frequent but serious events documented in regulatory prescribing information include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Rare systemic effects like blood dyscrasias and respiratory depression are also listed under their respective System-Organ Classes.


Safety Patterns and Specific Considerations

Official documents define certain risks related to exposure duration and patient characteristics:

Safety Consideration Regulatory Note
Population Specific Older adults may show increased sensitivity to CNS depression; caution is required in patients with hepatic or renal impairment.
Exposure Related Long-term exposure is formally associated with the risk of developing physical and psychic dependence, and potential issues with bone mineral density (osteoporosis).
Serious Constraint The medicine is formally contraindicated in conditions such as known hypersensitivity to barbiturates, severe respiratory insufficiency, or severe impairment of liver or kidney function.

This information structures the understanding of Crisax risks by communicating the difference between common, expected CNS effects and rare, but clinically important, systemic and dermatologic adverse reactions.

Overdose and Emergency Response

Crisax overdose manifestations are primarily classified by regulatory authorities as severe and potentially life-threatening due to the presence of a barbiturate component. Documented signs of overdose center on profound Central Nervous System (CNS) depression, presenting as stupor, deep coma, confusion, and loss of motor coordination (ataxia). Critical physiological effects include severe respiratory depression, often leading to slowed or absent breathing (apnea), and hypotension which may progress to circulatory collapse.

Overdose carries the risk of serious outcomes, including renal failure, cardiovascular collapse, and, due to the combination’s other components, fatal hyperkalemia or chronic Bromism. Regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose event, and emergency services must be contacted immediately.

Official prescribing information notes that no specific antidote is known for this overdose. Management is therefore limited to symptomatic and supportive therapy, which may involve procedural steps such as gastric lavage, administration of activated charcoal, and, in severe cases, the use of dialysis. Population-specific considerations also exist, noting that overdose in children or elderly patients may paradoxically present as excitement, and patients with impaired renal function face increased risk of toxicity.

Therapeutic Uses of Crisax

What Crisax Treats: Main Uses and Benefits

The therapeutic scope of Crisax is used across therapeutic domains involving symptoms related to heightened physiological activity to offer supportive symptomatic relief in non-severe presentations. The active components are commonly used to relieve anxiety and may assist with the management of a sedative effect. Crisax is primarily used in situations involving certain distressing symptoms and applied across therapeutic domains where additional symptomatic support is needed for nervous system regulation.

The medication is commonly used to help with excessive nervous tension, inner restlessness, functional irritability, and emotional lability linked to general nervous distress.

“Crisax is relevant for managing symptoms that interfere with daily comfort.”

It is applied during phases of increased distress or discomfort, where symptoms become temporarily overwhelming, and contributes to easing the overall symptom load when nervous symptoms are more noticeable. The drug is relevant when supportive symptom management is appropriate, provides supportive relief when symptoms interfere with routine activities during symptomatic periods.


Contextual Note on Symptom Management: Relief for Nervous Tension

The medication plays a role in managing symptoms that create noticeable physiological strain, and is applied in addressing episodic manifestations of excitement and mild agitation.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Crisax? — Official Regulatory Information

Crisax is for use only in the adult population (18 years and older) and its eligibility is strictly limited by the regulatory profile of its barbiturate and bromide components. The medicine is contraindicated in patients with a known hypersensitivity to any ingredient, acute intermittent porphyria, or pre-existing severe conditions such as severe respiratory depression, severe hepatic impairment, or severe renal impairment. It must also not be used by individuals with a history of drug abuse or dependence or those with untreated severe depression or high suicidal potential.

Use is not recommended in certain life stages. Crisax is contraindicated during pregnancy and breastfeeding due to the potential for harm to the fetus or infant. It is also not recommended for use in children and adolescents under 18 years as safety and efficacy in this age group are not established by regulatory documents. Older adults may use the medicine but require special caution and lower doses due to increased sensitivity and risk of adverse effects. Patients with mild-to-moderate liver or kidney impairment also require cautious use.

What should I know about interactions with other medicines?

Crisax contains phenobarbital, potassium bromide, and bromocamphor. The documented interactions profile is primarily driven by the properties of phenobarbital, which is a known potent enzyme inducer that can affect the concentration of many other medicinal products.

Interaction scope

Interaction Domain Relevant Medicinal Product Categories
Enzyme Induction Products metabolized by liver enzymes, notably CYP3A4 and CYP2C9
Central Nervous System (CNS) Depression Other CNS depressants (e.g., alcohol, opioids, sedatives)
Electrolyte/Renal Effects Products affecting chloride and potassium levels or renal function

Interaction-Related Restrictions and Constraints

Regulatory documents emphasize that Crisax, due to its phenobarbital content, must be used with caution with drugs that are metabolized by liver enzymes, as its enzyme-inducing effects can reduce the concentration and therapeutic effect of co-administered medicines. Conversely, co-administration with other CNS depressants may lead to additive effects, necessitating caution and monitoring.

  • Interacting Products/Classes: Official labeling identifies numerous specific drugs and classes, including certain anticoagulants, hormonal contraceptives, and corticosteroids, where reduced effectiveness is a risk due to phenobarbital's enzyme-inducing activity. Concomitant use with other bromides or drugs affecting renal clearance also requires consideration.

  • Practical Implication: The core constraint is the need for therapeutic drug monitoring and potential dose adjustment for the interacting product to ensure efficacy is maintained. Avoidance or careful monitoring is required for combinations with additive CNS-depressing effects.

Mechanism of Action

How Crisax Works

Crisax operates through an additive, multi-target mechanism that converges to reduce Central Nervous System ( CNS) excitability by enhancing the brain’s natural inhibitory processes and reinforcing neuronal function.


Enhancing GABAergic Inhibitory Signaling

The primary mechanism is achieved by Phenobarbital, which functions as a positive allosteric modulator of the gamma-Aminobutyric acid type A ( GABA A) receptor complex. This action prolongs the opening of the receptor's chloride ( Cl^-) ion channel, facilitating a greater influx of negative charge into the neuron. This molecular event causes neuronal hyperpolarization, which decreases the probability of neuronal action potential generation, resulting in a reduction of local and network-wide electrical signaling.


Generalized Neuronal Modulation via Ion Competition

The combination's mechanism is complemented by Potassium Bromide, where the Bromide^- ion ( Br^-) acts as a competitive anion in the CNS, partially substituting for Cl^- across neuronal membranes. This unique mechanism is independent of specific receptor binding and works to modulate the neuronal resting membrane potential. The resulting physiological change is a diffuse, systemic dampening of electrical activity that combines with the inhibitory effects established by the Phenobarbital component across large areas of the nervous system.


Mechanistic Additivity and Time Profile Constraint

The integration of the targeted GABA A potentiation and the broad ionic modulation ensures the mechanism achieves a sustained reduction in global CNS electrical activity. This sustained reduction in electrical signaling is the core physiological consequence. The mechanism, however, is constrained by the very long biological half-life of the Bromide^- component, meaning the full extent of the mechanistic activity is achieved and reversed slowly.

Dosage and Administration Information

How to Use Crisax

Crisax is prescribed as an oral medication administered in a Fixed-Dose Combination (FDC) tablet or capsule form. The medicine is taken by mouth, and its use is strictly guided by regulatory instructions regarding dosage, frequency, and duration.


Standard Administration Protocol

The therapeutic dosage is always individualized based on the patient’s condition and response. For adult sedative usage, the total daily dose, benchmarked by the core active ingredient, typically falls within the established 30 mg to 120 mg range. To ensure consistent systemic levels, the total daily amount must be divided and administered in two or three separate doses throughout the day. There is no specific timing instruction related to meals; the focus is on maintaining the divided daily schedule.


Procedural Constraints and Adjustments

The administration protocol requires specific adjustments for certain patient groups. A reduced dosage is a mandatory principle for both older adults and debilitated patients, as well as for those with confirmed hepatic or renal impairment. These modifications are necessary to account for altered metabolism and excretion. Furthermore, official usage dictates that discontinuation of Crisax must follow a gradual dose reduction (tapering) schedule. This procedural step defines the proper procedure for concluding therapy. The duration of use is generally reserved for short-term symptomatic management only.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Crisax


Evidence for Use in Nervous Tension and Mild Anxiety States

Research regarding Crisax, the fixed-dose combination, was studied to explore whether it was associated with changes in general nervous excitability and restlessness, which are conditions characterized by fluctuating or episodic manifestations. The evidence base primarily includes historical cohort studies, case series, and documents from older regulatory bodies, rather than modern, large-scale controlled trials. In these settings, research examined outcomes related to physical discomfort and used patient-reported outcomes describing perceived discomfort.

These studies help show what has been observed so far, with studies reported changes measured during the study period related to symptoms of nervous tension over short periods. The evidence provides context regarding symptom patterns historically, which primarily reflect historical clinical practices. Certainty remains low due to the lack of recent, double-blind, randomized, placebo-controlled trials (RCTs). Therefore, long-term effects are not fully established, and current data provide limited information for long-term outcomes.


Evidence for Use in Symptomatic Sedation

The research structure supporting symptomatic sedation was evaluated based on pharmacological studies of its active ingredients, especially Phenobarbital. Studies monitored the degree of Central Nervous System (CNS) suppression, with data derived from research on the active ingredients. These findings described patterns observed in studies exploring the time required to achieve a noticeable sedative state. However, studies specifically addressing the three-component FDC for general, mild symptomatic calming are evidence is limited.


Long-Term Evidence and Follow-Up Duration

Research examined the effects of Crisax primarily over defined time intervals that were short-term in nature, meaning follow-up durations were limited. Consequently, there is limited information for long-term outcomes or the persistence of observed effects over months or years of use.


What is Still Uncertain About Crisax Research

The overall research base is limited by the lack of contemporary, high-quality Randomized Controlled Trials (RCTs). Comparative evidence is lacking to show how this combination compares in terms of studied outcomes against other treatments. The results apply only to the populations studied in those historical reports, meaning that the broader clinical applicability in current medical settings appears to remain an area where more research is ongoing but largely unavailable.

Key Studies & References

  1. MedlinePlus Drug Information: Overview of components commonly used to relieve anxiety (Used to establish anxiolytic context for active components)
  2. MedlinePlus Drug Information: General Overview (Used to establish historical context of Potassium Bromide component)
  3. Pharmacology and Established Clinical Use of Barbiturate Sedatives (Used for data supporting Symptomatic Sedation evidence)

Frequently Asked Questions (FAQ)

Common questions about Crisax (FAQ)


Q: How long does it usually take for a person to notice the effects of Crisax?

A: The active ingredients in Crisax have different time profiles for reaching stable levels in the body. While initial effects from one component may be seen within a few hours, reaching the full, stable therapeutic level may take days to weeks. This is attributed to the very long biological half-life of the bromide component, as described in official pharmacokinetic data.

Q: Is it common to feel worse when first starting Crisax?

A: According to official product information, sedative effects like drowsiness and impaired coordination are common during the initial days or weeks of treatment. Regulatory documents indicate these effects are often temporary and may lessen as an individual’s body adjusts.

Q: Do the side effects from Crisax usually lessen or go away over time?

A: These effects are often temporary and may become milder as the body adjusts to the drug’s presence over the initial phase of treatment. Official labeling suggests that individuals often see resolution of common side effects.

Q: Can Crisax cause symptoms of drowsiness or dizziness?

A: Yes, common adverse reactions listed in regulatory documents include drowsiness, sedation, and dizziness. Official documents caution that these effects may be associated with impaired mental or physical abilities required for performing potentially hazardous tasks, such as driving or operating machinery.

Q: Can Crisax cause dependence or withdrawal symptoms?

A: Long-term use of this medicine is associated with a risk of developing physical and psychic dependence. Official labeling states that withdrawal symptoms, including convulsions, may occur upon abrupt cessation after prolonged use. For this reason, official labeling specifies that discontinuation of therapy must be achieved through a gradual dose reduction (tapering) process.

Q: Are there any known foods or drinks that interact with Crisax?

A: Regulatory documents specifically caution against the use of alcohol due to the risk of additive central nervous system depressant effects. Specific non-alcoholic foods or drinks are generally not highlighted in the primary regulatory warnings.

Q: Is it safe to consume alcohol while taking Crisax?

A: Regulatory documents advise against the co-administration of alcohol while using this medicine. This is due to the potential for increased central nervous system depressant effects.

Q: Are there any specific herbal supplements or vitamins that interact with Crisax?

A: The phenobarbital component is a potent enzyme inducer, meaning it can affect the body's levels of certain supplements and vitamins (e.g., Folate, Vitamin D, Vitamin K). Official documentation or drug databases identify the potential for increased risk of sedation when co-administered with other sedative herbs, such as Kava or Valerian.

Q: How is Crisax different from [similar-sounding competitor drug]?

A: Official documentation is lacking in contemporary comparative evidence against other treatments. The medicine is a fixed-dose combination, and its mechanism involves combining a targeted receptor action (phenobarbital) with a broad ionic modulation (potassium bromide).

Q: What symptoms should make a person contact a doctor about Crisax?

A: Official labeling documents rare but serious side effects, including signs of severe skin reactions (like Stevens-Johnson Syndrome), or symptoms of blood dyscrasias or respiratory depression (difficulty breathing). Severe, unexpected, or rapidly worsening symptoms are regulatory points of concern that warrant professional evaluation.

Q: What happens if a person misses a dose of Crisax?

A: Regulatory guidance for a missed dose generally suggests taking the dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, official guidance indicates the missed dose is generally skipped, as this procedure is intended to prevent doubling the dose.

Q: Can Crisax be used by people who have liver problems?

A: Crisax is contraindicated (should not be used) for individuals with severe hepatic (liver) impairment. For those with mild-to-moderate impairment, official guidance notes that use requires special caution and consideration for the body’s altered ability to process the medicine.

Q: Does Crisax have any warnings related to pre-existing heart conditions?

A: Regulatory documents primarily emphasize caution for patients with severe impairment of the respiratory system, liver, or kidneys. No general warnings or contraindications are typically listed regarding common pre-existing heart conditions.

Q: How long have doctors been prescribing Crisax?

A: The active components, Potassium Bromide and Phenobarbital, have a very long history of medical use, dating back to the 19th and early 20th centuries. This long history of use is reflected in the medicine's research base, which includes historical studies.

How should Crisax be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documentation for Crisax states that the product does not require any special storage conditions for the veterinary medicine as packaged for sale. The medicine has a designated shelf life of 3 years when stored in its original commercial container.


Labeled Stability / Container Rules
Shelf life is 3 years as packaged for sale.
Must be stored in the original container with a child-resistant safety cap intact.

Official Disposal Mandates
Do not dispose of unused or expired medicine in the sewage system or household waste.
Disposal must follow current regulations on waste for unused medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Crisax found in:

A-Z Index: